Total Health
Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.
For more info visit our website at Total Health.
Boston
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Low-grade Lymphoma Highlights: Is CD19 CAR-T Axi-cel Active in R/R Indolent NHLs? Does BOVen (Zanubrutinib, Obinutuzumab, Venetoclax) Achieve Frequent uMRD in 1L CLL? Is 2nd Generation BTKi Zanubrutinib Better Than Ibrutinib in WM?
FEATURING
Jake Soumerai
- 567 views
- July 22, 2020
- 5
2020 ASCO Virtual Direct™ Highlights
ASCO Update on CML: What Is the Optimal Ponatinib Dosing in Chronic Phase CML?
FEATURING
Tapan Kadia
- 89 views
- July 22, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Ovarian Cancer Update: Efficacy Analysis of Non-chemo Options for Platinum Sensitive Relapse
FEATURING
Rebecca Stone
- 713 views
- July 16, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Improvements in Endometrial Cancer: Single Agent IO in “Non-biomarker” Selected Patients, Cabozantinib + Nivolumab in Advanced Recurrent Metastatic Disease, anti-HER-2 in Advanced or Recurrent Uterine Serous Carcinoma
FEATURING
Rebecca Stone
- 50 views
- July 16, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on TNBC & HR+ MBC: Analysis & Comparison of 1st Line Options for PD-L1 +/- Cancers With(out) BRCA 1/2. Exploring the Optimal ET Agent to Combine With Palbociclib in the First-line Endocrine-sensitive Disease
FEATURING
Ian Krop
- 703 views
- July 13, 2020
- 4
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on HER2+ Neoadjuvant BC: Which Pts Are Candidates for Preoperative Systemic Therapy in Early Stage Setting? Is Therapy With Anthracyclines Inevitable? How Can We Shorten Duration Trastuzumab?
FEATURING
Reshma L. Mahtani
- 19 views
- July 13, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Adjuvant Therapy in HER2+ BC: Utilizing T-DM1 for Pts With Residual Disease vs. Extending Adjuvant Therapy With 1 yr of Neratinib vs. Adding Pertuzumab + SoC Trastuzumab - Which Option Provides Better Results?
FEATURING
Reshma L. Mahtani
- 21 views
- July 13, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Diagnostic/Prognostic Testing in PC: Is 68Ga- PSMA-11 PET More Accurate for Detection of N1 vs. Histopathology at Time of RP? Is 18F-DCFPyL PET/CT More Sensitive for Detection of Recurrent Disease vs. Standard Imaging Agents?
FEATURING
William Kelly
- 101 views
- July 15, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on 1st Line IO Strategies for Metastatic NSCLC: Should CheckMate 227 (Ipi + Nivo) and CheckMate 9LA (Nivo/Ipi + Chemo) Data Change My Practice? Tiragolumab/Atezolizumab Shows Promising Activity in PD-L1+ NSCLC
FEATURING
Ibiayi Dagogo-Jack
- 740 views
- July 13, 2020
- 1